Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan

Abstract The chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shigeru Honda, Yasuo Yanagi, Hideki Koizumi, Yirong Chen, Satoru Tanaka, Manami Arimoto, Kota Imai
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8ce84e6008ee465eb86250e26c63d5c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ce84e6008ee465eb86250e26c63d5c7
record_format	dspace
spelling	oai:doaj.org-article:8ce84e6008ee465eb86250e26c63d5c72021-12-02T17:12:18ZImpact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan10.1038/s41598-021-92567-42045-2322https://doaj.org/article/8ce84e6008ee465eb86250e26c63d5c72021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92567-4https://doaj.org/toc/2045-2322Abstract The chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using data from the Japan National Health and Wellness surveys 2009–2014. Out of 147,272 respondents, 100 nAMD patients reported currently receiving treatment. Controls without nAMD were selected by 1:4 propensity score matching. Healthcare Resource Utilisation (HRU), Health-Related Quality of Life (HRQoL), and work productivity loss were compared between the groups. Regarding HRU, nAMD patients had significantly increased number of visits to any healthcare provider (HCP) (13.8 vs. 8.2), ophthalmologist (5.6 vs. 0.8), and other HCP (9.5 vs. 7.1) compared to controls after adjusting for confounding factors. Additionally, nAMD patients had reduced HRQoL and work productivity, i.e., reduced physical component summary (PCS) score (46.3 vs. 47.9), increased absenteeism (18.14% vs. 0.24%), presenteeism (23.89% vs. 12.44%), and total work productivity impairment (33.57% vs. 16.24%). The increased number of ophthalmologist visits were associated with decreased PCS score, increased presenteeism and total work productivity impairment. The current study highlighted substantial burden for nAMD patients, requiring further attention for future healthcare planning and treatment development.Shigeru HondaYasuo YanagiHideki KoizumiYirong ChenSatoru TanakaManami ArimotoKota ImaiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shigeru Honda Yasuo Yanagi Hideki Koizumi Yirong Chen Satoru Tanaka Manami Arimoto Kota Imai Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan
description	Abstract The chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using data from the Japan National Health and Wellness surveys 2009–2014. Out of 147,272 respondents, 100 nAMD patients reported currently receiving treatment. Controls without nAMD were selected by 1:4 propensity score matching. Healthcare Resource Utilisation (HRU), Health-Related Quality of Life (HRQoL), and work productivity loss were compared between the groups. Regarding HRU, nAMD patients had significantly increased number of visits to any healthcare provider (HCP) (13.8 vs. 8.2), ophthalmologist (5.6 vs. 0.8), and other HCP (9.5 vs. 7.1) compared to controls after adjusting for confounding factors. Additionally, nAMD patients had reduced HRQoL and work productivity, i.e., reduced physical component summary (PCS) score (46.3 vs. 47.9), increased absenteeism (18.14% vs. 0.24%), presenteeism (23.89% vs. 12.44%), and total work productivity impairment (33.57% vs. 16.24%). The increased number of ophthalmologist visits were associated with decreased PCS score, increased presenteeism and total work productivity impairment. The current study highlighted substantial burden for nAMD patients, requiring further attention for future healthcare planning and treatment development.
format	article
author	Shigeru Honda Yasuo Yanagi Hideki Koizumi Yirong Chen Satoru Tanaka Manami Arimoto Kota Imai
author_facet	Shigeru Honda Yasuo Yanagi Hideki Koizumi Yirong Chen Satoru Tanaka Manami Arimoto Kota Imai
author_sort	Shigeru Honda
title	Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan
title_short	Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan
title_full	Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan
title_fullStr	Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan
title_full_unstemmed	Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan
title_sort	impact of neovascular age-related macular degeneration: burden of patients receiving therapies in japan
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8ce84e6008ee465eb86250e26c63d5c7
work_keys_str_mv	AT shigeruhonda impactofneovascularagerelatedmaculardegenerationburdenofpatientsreceivingtherapiesinjapan AT yasuoyanagi impactofneovascularagerelatedmaculardegenerationburdenofpatientsreceivingtherapiesinjapan AT hidekikoizumi impactofneovascularagerelatedmaculardegenerationburdenofpatientsreceivingtherapiesinjapan AT yirongchen impactofneovascularagerelatedmaculardegenerationburdenofpatientsreceivingtherapiesinjapan AT satorutanaka impactofneovascularagerelatedmaculardegenerationburdenofpatientsreceivingtherapiesinjapan AT manamiarimoto impactofneovascularagerelatedmaculardegenerationburdenofpatientsreceivingtherapiesinjapan AT kotaimai impactofneovascularagerelatedmaculardegenerationburdenofpatientsreceivingtherapiesinjapan
_version_	1718381446216810496

Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan

Ejemplares similares